Systemic pulmonary events associated with ...
Type de document :
Article dans une revue scientifique: Article original
DOI :
PMID :
URL permanente :
Titre :
Systemic pulmonary events associated with myelodysplastic syndromes: a retrospective multicentre study
Auteur(s) :
Scanvion, Quentin [Auteur]
Université Lille Nord (France)
Pascal, Laurent [Auteur]
Hôpital Saint Vincent de Paul [Lille]
Sy, Thierno [Auteur]
Stervinou-Wemeau, Lidwine [Auteur]
Service de Pneumologie et Immuno-Allergologie [CHU LIlle]
Lejeune, Anne-Laure [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Deken, Valerie [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Hachulla, Eric [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Quesnel, Bruno [Auteur]
Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) - UMR 9020 - UMR 1277
Miniaturisation pour la Synthèse, l'Analyse et la Protéomique (MSAP) - USR 3290
Mekinian, Arsene [Auteur]
CHU Saint-Antoine [AP-HP]
Launay, David [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Terriou, Louis [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Laurent, Pascal [Auteur]
Université Lille Nord (France)
Pascal, Laurent [Auteur]
Hôpital Saint Vincent de Paul [Lille]
Sy, Thierno [Auteur]
Stervinou-Wemeau, Lidwine [Auteur]
Service de Pneumologie et Immuno-Allergologie [CHU LIlle]
Lejeune, Anne-Laure [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Deken, Valerie [Auteur]

METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Hachulla, Eric [Auteur]

Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Quesnel, Bruno [Auteur]

Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) - UMR 9020 - UMR 1277
Miniaturisation pour la Synthèse, l'Analyse et la Protéomique (MSAP) - USR 3290
Mekinian, Arsene [Auteur]
CHU Saint-Antoine [AP-HP]
Launay, David [Auteur]

Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Terriou, Louis [Auteur]

Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Laurent, Pascal [Auteur]
Titre de la revue :
Journal of clinical medicine
Nom court de la revue :
J Clin Med
Numéro :
10
Pagination :
1162
Éditeur :
MDPI
Date de publication :
2021-03-10
ISSN :
2077-0383
Mot(s)-clé(s) :
iatrogenic effects
pulmonary hypertension
pleuritic effusion
pneumonia
interstitial lung disease
pulmonary alveolar proteinosis
pulmonary hypertension
pleuritic effusion
pneumonia
interstitial lung disease
pulmonary alveolar proteinosis
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Although pulmonary events are considered to be frequently associated with malignant haemopathies, they have been sparsely studied in the specific context of myelodysplastic syndromes (MDS). We aimed to describe their ...
Lire la suite >Although pulmonary events are considered to be frequently associated with malignant haemopathies, they have been sparsely studied in the specific context of myelodysplastic syndromes (MDS). We aimed to describe their different types, their relative proportions and their relative effects on overall survival (OS). We conducted a multicentre retrospective cohort study. Patients with MDS (diagnosed according to the 2016 WHO classification) and pulmonary events were included. The inclusion period was 1 January 2007 to 31 December 2017 and patients were monitored until August 2019. Fifty-five hospitalized patients were included in the analysis. They had 113 separate pulmonary events. Thirteen patients (23.6%) had a systemic autoimmune disease associated with MDS. Median age at diagnosis of MDS was 77 years. Median time to onset of pulmonary events was 13 months. Pulmonary events comprised: 70 infectious diseases (62%); 27 interstitial lung diseases (23.9%), including 13 non-specific interstitial pneumonias and seven secondary organizing pneumonias or respiratory bronchiolitis-interstitial lung diseases; 10 pleural effusions (8.8%), including four cases of chronic organizing pleuritis with exudative effusion; and six pulmonary hypertensions (5.3%). The median OS of the cohort was 29 months after MDS diagnosis but OS was only 10 months after a pulmonary event. The OS was similar to that of the general myelodysplastic population. However, the occurrence of a pulmonary event appeared to be either an accelerating factor of death or an indicator for the worsening of the underlying MDS in our study. More than a third of pulmonary events were non-infectious and could be systemic manifestations of MDS.Lire moins >
Lire la suite >Although pulmonary events are considered to be frequently associated with malignant haemopathies, they have been sparsely studied in the specific context of myelodysplastic syndromes (MDS). We aimed to describe their different types, their relative proportions and their relative effects on overall survival (OS). We conducted a multicentre retrospective cohort study. Patients with MDS (diagnosed according to the 2016 WHO classification) and pulmonary events were included. The inclusion period was 1 January 2007 to 31 December 2017 and patients were monitored until August 2019. Fifty-five hospitalized patients were included in the analysis. They had 113 separate pulmonary events. Thirteen patients (23.6%) had a systemic autoimmune disease associated with MDS. Median age at diagnosis of MDS was 77 years. Median time to onset of pulmonary events was 13 months. Pulmonary events comprised: 70 infectious diseases (62%); 27 interstitial lung diseases (23.9%), including 13 non-specific interstitial pneumonias and seven secondary organizing pneumonias or respiratory bronchiolitis-interstitial lung diseases; 10 pleural effusions (8.8%), including four cases of chronic organizing pleuritis with exudative effusion; and six pulmonary hypertensions (5.3%). The median OS of the cohort was 29 months after MDS diagnosis but OS was only 10 months after a pulmonary event. The OS was similar to that of the general myelodysplastic population. However, the occurrence of a pulmonary event appeared to be either an accelerating factor of death or an indicator for the worsening of the underlying MDS in our study. More than a third of pulmonary events were non-infectious and could be systemic manifestations of MDS.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
CHU Lille
CNRS
Inserm
Université de Lille
CNRS
Inserm
Université de Lille
Collections :
Date de dépôt :
2021-07-06T12:50:54Z
2022-11-16T08:00:26Z
2022-11-16T08:00:26Z
Fichiers
- jcm-10-01162-v5.pdf
- Non spécifié
- Accès libre
- Accéder au document